Recent advances in the treatment of GERD in the elderly: Focus on proton pump inhibitors

International Journal of Clinical Practice

Volumn 59, Issue 10, 2005, Pages 1204-1209

  Pilotto, Alberto ^a   Franceschi, M ^a   Paris, F ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Aging; Gastroesophageal disease; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZITHROMYCIN; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CISAPRIDE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NITRIC ACID DERIVATIVE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; POTASSIUM SALT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABEPRAZOLE; RANITIDINE; SUCRALFATE; TETRACYCLINE; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ANTIULCER AGENT; PROTON PUMP;

AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ATROPHY; BEHAVIOR MODIFICATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPLASIA; ESOPHAGUS DISEASE; GASTROESOPHAGEAL REFLUX; GERIATRIC CARE; GERIATRIC PATIENT; HEALING; HEARTBURN; HUMAN; INTESTINE METAPLASIA; LIFESTYLE; LONG TERM CARE; MAINTENANCE THERAPY; META ANALYSIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RECURRENT DISEASE; REFLUX ESOPHAGITIS; REVIEW; SHORT COURSE THERAPY; STOMACH ACID SECRETION; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT PLANNING; VOMITING; WEIGHT REDUCTION; ACUTE DISEASE; AGE; DRUG ANTAGONISM;

ACUTE DISEASE; AGE FACTORS; AGED; ANTI-ULCER AGENTS; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMPS; RECURRENCE;

EID: 33644840714     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00639.x     Document Type: Review

References (50)

1. Veldhuyzen van Zanten SJ, Flook N, Chiba N et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pyl ori. Canadian Dyspepsia Working Group. CMAJ 2000; 162: S3-23.
2. Haag S, Holtmann G. Reflux disease and Barrett's esophagus. Endoscopy 2003; 35: 112-7.
3. Mold JW, Reed LE, Davis AB et al. Prevalence of gastroesophageal reflux in elderly patients in a primary care setting. Am J Gastroenterol 1991; 86: 965-70.
4. Maekawa T, Kinoshita Y, Okada A et al. Relationship between severity and symptoms of reflux esophagitis in elderly patients in Japan. J Gastroenterol Hepatol 1998; 13: 927-30.
5. el-Serag HB, Sonnenberg A. Associations between different forms of gastro-esophageal reflux disease. Gut 1997; 41: 594-9.
6. Pilotto A, Franceschi M, Orsitto G, Cascavilla L. Ageing and the gastrointestinal tract in autonomic nervous system in old age. In: Kuchel GA, Hof PR, eds. Interdisciplinary Topics in Gerontology Basel: Karger Press, 2004; 33: 67-77.
7. Raiha I, Hietanen E, Sourander L. Symptoms of gastro-esophageal reflux disease in elderly people. Age Ageing 1991; 20: 365-70.
8. Pilotto A, Franceschi M. Gastro-esophageal reflux disease in the elderly. In: Pilotto A, Malfertheiner P, Holt P, eds. Aging and the Gastrointestinal Tract. Interdisciplinary Topics in Gerontology Basel: Karger Press, 2003; 32: 100-17.
9. Zimmerman J, Shohat V, Tsvang E et al. Esophagitis is a major cause of upper gastrointestinal hemorrhage in the elderly. Scand J Gastroenterol 1997; 32: 906-9.
10. Stanghellini V, Armstrong D, Monnikes H et al. Epidemiological evaluation of gastroesophageal reflux disease (GERD)-associated symptoms in healthy subjects. Gastroenterology 2004; 4 (Suppl. 2): A328 [Abstract]
11. Richter JE. Gastroesophageal reflux disease in the older patient: presentation, treatment, complications Am J Gastroenterol 2000; 95: 368-73.
12. Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-esophageal reflux disease: The role of drug interactions. Clin Pharmacokinet 2000; 39: 295-309.
13. Dajani EZ. Gastroesophageal reflux disease: Pathophysiology and pharmacology overview. J Assoc Acad Minor Phys 2000; 11: 7-11.
14. 2 -receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol 2001; 15: 355-70.
15. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. The Cochrane Database Systematic Rev 2004: CD002095.
16. Kovacs TOG, Wilcox CM, DeVault K et al. Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive esophagitis: A randomised, active-controlled, double-blind study. Aliment Pharmacol Ther 2002; 16: 2043-52.
17. Gillen D, McColl KE. Problems related to acid rebound and tachyphylaxis. Best Pract Res Clin Gastroenterol 2001; 15: 487-95.
18. Pilotto A, Leandro G, Franceschi M. Short- and long-term therapy for reflux esophagitis in the elderly: A multi-centre, placebo-controlled study with pantoprazole. Aliment Pharmacol Ther 2003; 17: 1399-406.
19. Thjodleifsson B. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drugs Aging 2002; 19: 911-27.
20. Wilcox CM, Heudebert G, Klapow J et al. Survey of primary care physicians' approach to gastroesophageal reflux disease in elderly patients. J Gerontol A Biol Sci Med Sci 2001; 56: M514-7.
21. Thomson AB, Chiba N, Armstrong D et al. The Second Canadian Gastroesophageal Reflux Disease Consensus: Moving forward to new concepts. Can J Gastroenterol 1998; 12: 551-6.
22. Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000; 6 (Suppl.): S491-505.
23. Lagergren J, Bergstrom R, Adami HO, Nyren O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000; 133: 165-75.
24. Lanas AI, Sousa FL, Ortego J et al. Aspirin renders the esophageal mucosa more permeable to acid and pepsin. Eur J Gastroenterol Hepatol 1995; 7: 1065-72.
25. Abraham SC, Cruz-Correa M, Lee LA, Yardley JH, Wu TT. Alendronate-associated esophageal injury: Pathologic and endoscopic features. Mod Pathol 1999; 12: 1152-7.
26. Alphin RS, O'Dell SW, Sancilio LF, Ward JW. Irritative properties of two clinical potassium chloride formulations on duodenal mucosa of the cat and esophageal mucosa of the opossum. Dig Dis Sci 1984; 29: 508-12.
27. Carlborg B, Densert O. Esophageal lesions caused by orally administered drugs. An experimental study in the cat. Eur Surg Res 1980; 12: 270-82.
28. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997; 112: 1798-810.
29. 2 -receptor antagonists in the treatment of elderly and young patients with reflux esophagitis. Age Ageing 1994; 23: 121-6.
30. Pilotto A, Franceschi M, Leandro G et al. Efficacy and tolerability of proton pump inhibitors in the short term treatment of esophagitis in elderly patients. Gut 2002; 51 (Suppl. 3): A167.
31. Reuss JM on behalf of GERyEAP Residencias. Tolerability and effectiveness of pantoprazole (PAN) in the elderly population with peptic acid-related disease (PAD) Rev Esp Geriatr Gerontol 2003; 38 (Suppl. 1): 148 [abstract].
32. DeVault KR, Lynn RB, Bochenek WJ et al. Successful treatment of elderly patients with erosive esophagitis (EE) using pantoprazole 40 mg. Am J Gastroenterol 2003: September (Suppl.), S3 [Abstract].
33. Carlsson R, Galmiche JP, Dent J et al. Prognostic factors influencing relapse of esophagitis during maintenance therapy with antisecretory drugs: A meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 473-82.
34. McDougall NI, Johnston BT, Kee F et al. Natural history of reflux esophagitis: A 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996; 38: 481-6.
35. Pilotto A, Franceschi M, Leandro G et al. Long-term clinical outcome of elderly patients with reflux esophagitis: A six-month to three-year follow-up study. Am J Ther 2002; 9: 295-300.
36. Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: A systematic overview. Can J Gastroenterol 1997; 11 (Suppl. B): 66B-73B.
37. Vigneri S, Termini R, Leandro G et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10.
38. Escourrou J, Deprez P, Saggioro A et al. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux esophagitis. Aliment Pharmacol Ther 1999; 13: 1481-91.
39. Hatlebakk JG, Berstad A. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux esophagitis. Aliment Pharmacol Ther 1997; 11: 365-72.
40. Klotz U. Effect of aging on the pharmacokinetics of gastrointestinal drugs. In: Pilotto A, Malfertheiner P, Holt P, eds. Aging and the Gastrointestinal Tract. Interdisciplinary Topics in Gerontology Basel: Karger 2003; 32: 28-39.
41. Flouvat B, Delhotal-Landes B, Cournot A, Dellatolas F. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br J Clin Pharmacol 1993; 36: 467-9.
42. Huber R, Hartmann M, Bliesath H et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996; 34: 185-94.
43. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28.
44. Hasselgren G, Hassan-Alin M, Andersson T et al. Pharmacokinetic study of esomeprazole in the elderly. Clin Pharmacokinet 2001; 40: 145-50.
45. Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole: An update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63: 101-33.
46. Ferron GM, Preston RA, Noveck RJ et al. Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. Clin Ther 2001; 23: 1180-92.
47. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 2000; 38: 243-70.
48. Simon WA. Pantoprazole -Which cytochrome P450 isozymes are involved in its biotransformation? Gut 1995; 37 (Suppl. 2): 1177.
49. Klinkenberg-Knol EC, Nelis F, Dent J et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9.
50. Bardhan KD, Cherian P, Bishop AE et al. Pantoprazole therapy in the long-term management of severe acid peptic disease: Clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. Am J Gastroenterol 2001; 96: 1767-76.